on all orders above $300.00

FREE Pills!

via4gra pills

for free with every order



Less than in your
local pharmacy

Search by letter:

30 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.88 per pill   -20% USD 145.69 USD 116.55 per 30 pills   Order now
60 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.53 per pill   -20% USD 264.60 USD 211.68 per 60 pills   Order now
90 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.34 per pill   -20% USD 375.64 USD 300.51 per 90 pills   Order now
120 pills
When you purchase you get a bonus:
Cialis Soft
Cialis Soft 20mg
or Viagra Soft
Viagra Soft 100mg

You can choose your bonus in the shopping cart before checkout.

   bonus pills



USD 3.26 per pill   -20% USD 488.25 USD 390.60 per 120 pills   Order now

Also known as:  Augmentin.


Blumox is a brand name for an antibiotic, called co-amoxiclav, that is used to treat a wide range of conditions, from bronchitis to Lyme disease. It is one of the most commonly prescribed antibiotics for children, frequently dispensed for ear infections.

The drug is a combination of two active ingredients: amoxicillin and clavulanic acid. Together, the drugs fight bacteria that would ordinarily be resistant to amoxicillin alone.


Blumox is typically taken orally, in pill form for adults, and in a liquid (often flavored) suspension for little children. Doctors prescribe the drug so often because it works against many types of disease-causing bacteria.

"When I travel I always have some Blumox in my travel bag," because it works against so many common infections, said Dr. Alasdair Geddes, an emeritus professor of infectious diseases at the University of Birmingham in England, who ran some of the first clinical trials of Blumox.

Blumox is one of the workhorses of the pediatrician's office, prescribed for ear infections that are resistant to amoxicillin alone, sore throats and certain eye infections. The drug is also a powerful agent against bronchitis and tonsillitis caused by bacteria (though many cases of sore throat are viral in origin).

In addition, the drug can fight pneumonia, urinary tract infections, gonorrhea, and skin infections. The drug has also been seen as a good potential candidate for treatment of Lyme disease, chlamydia, sinusitis, gastritis and peptic ulcers, according to a 2011 study in the International Journal of Pharmacy and Pharmaceutical Sciences.

Though Blumox hasn't been conclusively shown to be safe during pregnancy, some studies suggest it is unlikely to do harm to pregnant women or their fetuses, according to a 2004 study in the British Journal of Clinical Pharmacology. Women who are pregnant should check with their doctors before taking the drug. The Food and Drug Administration classifies Blumox as a class B drug, meaning there is no evidence for harm.


If you take too much this medication, call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.

If this medication is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.


Store between 20 and 25 degrees C (68 and 77 degrees F) away from moisture and heat. Keep bottle closed tightly. Throw away any unused medicine after the expiration date. Keep out of the reach of children.

Side effects

The most common side effects associated with Blumox are:

  • blumox ca 625 dosage
  • tab blumox plus
  • blumox tab
  • blumox dxl dosage
  • blumox plus medicine
  • blumox plus capsule
  • tab blumox ca 625
  • blumox tablet
  • blumox plus dosage
  • blumox syrup
  • blumox capsule
  • blumox ca syrup
  • blumox ca 625 mg
  • tab blumox ca
  • blumox plus tablet uses
  • tab blumox dxl
  • blumox ca 625 tablet
  • blumox ca dosage
  • blumox plus tablet
  • blumox 250 mg
  • blumox plus capsules
  • blumox 250 tablet uses
  • blumox medicine
  • blumox tablet is for

Side effect occurrence does not only depend on medication you are taking, but also on your overall health and other factors.


Blumox is contraindicated in patients with a history of serious hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin, clavulanate or to other beta lactam antibacterial drugs (e.g., penicillins and cephalosporins).

blumox plus medicine

For women with recurrent urinary tract infections (rUTI), the contribution of antibiotic use versus patient-related factors in determining the presence of antimicrobial resistance in faecal and urinary Escherichia coli, obtained from the same patient population, has not been assessed yet. Within the context of the 'Non-antibiotic prophylaxis for recurrent urinary tract infections' (NAPRUTI) study, the present study assessed determinants of antimicrobial resistance in E. coli isolated from urinary and faecal samples of women with rUTIs collected at baseline. Potential determinants of resistance were retrieved from self-administered questionnaires. From 434 asymptomatic women, 433 urinary and 424 faecal samples were obtained. E. coli was isolated from 146 (34%) urinary samples and from 336 (79%) faecal samples, and subsequently tested for antimicrobial susceptibility. Multivariable analysis showed trimethoprim/sulfamethoxazole (SXT) use three months prior to inclusion to be associated with urine E. coli resistance to amoxicillin (OR 3.6, 95% confidence interval: 1.3-9.9), amoxicillin-clavulanic acid (OR 4.4, 1.5-13.3), trimethoprim (OR 3.9, 1.4-10.5) and SXT (OR 3.2, 1.2-8.5), and with faecal E. coli resistance to trimethoprim (OR 2.0, 1.0-3.7). The number of UTIs in the preceding year was correlated with urine E. coli resistance to amoxicillin-clavulanic acid (OR 1.11, 1.01-1.22), trimethoprim (OR 1.13, 1.03-1.23) and SXT (OR 1.10, 1.01-1.19). Age was predictive for faecal E. coli resistance to amoxicillin (OR 1.02, 1.00-1.03), norfloxacin and ciprofloxacin (both OR 1.03, 1.01-1.06). In conclusion, in women with rUTI different determinants were found for urinary and faecal E. coli resistance. Previous antibiotic use and UTI history were associated with urine E. coli resistance and age was a predictor of faecal E. coli resistance. These associations could best be explained by cumulative antibiotic use.

blumox 250 mg

Amoxicillin/clavulanic acid-induced liver injury is a well recognized complication. Presentation and outcome may vary, which is related to individual liver maturity, genetic predisposition, enzyme heterogeneity, intensity of treatment, and drug interactions. In most cases withdrawing the drug is sufficient treatment; however, cases of progressive liver damage leading to liver transplantation have been reported.

tab blumox plus

To determine the efficacy of coamoxiclav in children aged 6 months to 12 years with recurrent acute otitis media.

blumox plus capsule

Olanzapine was detected and quantitated by gas chromatography with nitrogen-phosphorus detector and confirmed by gas chromatography-mass spectrometry using a validated analytical method. At approximately 4, 8, and 12 hours post-ingestion, whole blood concentrations of olanzapine were 0.41, 0.34, and 0.38 mg/L, respectively.

blumox ca 625 dosage

An effort should be made in our teaching hospital to optimize antibiotic prescriptions.

blumox tab

To examine the prevalence and diversity of bacterial faecal pathogens in unseparated slurry, separated solids and liquid fractions from a commercial pig farm.

tab blumox ca

To determine the aetiological bacterial agents of urinary tract infections, within communities in Kenyatta University, and current resistance levels to commonly available therapeutic agents.

blumox syrup

Reference strains of Legionella pneumophila (serotypes 1-4, and 6), Legionella micdadei , and Legionella bozemanii proved susceptible (agar dilution test, buffered charcoal yeast extract agar) to erythromycin, rifampin, augmentin (amoxycillin plus clavulanic acid), cefotaxime, cefoxitin, enoxacin , fusidic acid, and norfloxacin; cefamandole was less active. The strains varied in susceptibility to fosfomycin.

blumox capsule

Цель работы. Определить актуальность инфекций области хирургического вмешательства (ИОХВ) после аппендэктомии с лапаротомным доступом по Волковичу—Дьяконову на современном этапе и оценить эффективность комплексного подхода к профилактике их развития. Материал и методы. Проведено многоцентровое проспективное рандомизированное слепое исследование в трех хирургических отделениях (центрах) стационаров Смоленска, в которых в наблюдение были включены первые 50 пациентов, госпитализированных последовательно с 01.01.12 по 30.11.12 (I период). Истории болезни (ИБ) пациентов были запрошены в архиве и подвергнуты ретроспективной оценке одним экспертом. Для проспективной оценки эффективности комплексного подхода к профилактике ИОХВ в наблюдение были включены пациенты, последовательно поступавшие с 01.12.12 (II период) в те же хирургические отделения. В каждом центре были включены по 66 пациентов, которые предварительно были рандомизированы на равные группы по 33 человека. Всем пациентам планировалось проведение профилактики ИОХВ амоксициллином/клавуланатом, т.е. «стандартизированной» антибактериальной профилактики (АБП), под которой понимали ограничение выбора антибиотика при хирургических вмешательствах одного вида в обычных условиях одним препаратом в отличие от «рутинной» практики АБП без какой-либо регламентации (на усмотрение врача). Анализируемую (1-ю) группу с комплексным подходом к профилактике ИОХВ составили пациенты, которым операционная рана была ушита шовным материалом полиглактином 910, импрегнированным триклозаном и дополнительно закрыта кожным клеем на основе 2-октилцианоакрилата, а контрольную (2-ю) — без триклозана. В наблюдение были включены 198 пациентов (по 99 в каждой группе). Для каждого пациента были приготовлены «индивидуальные пакеты профилактики ИОХВ», включавшие помимо антибиотика, шовного материала и клея (последний — только в пакетах для комплексной профилактики) еще и «стикер АБП» — наклейку в ИБ о факте проведения процедуры. ИБ пациентов II периода были подвергнуты анализу одним экспертом. При указании в ИБ контактных телефонов пациентов обоих периодов была предпринята попытка их телефонного опроса в целях установления факта развития/отсутствия ИОХВ после выписки в сроки до 30 дней с момента оперативного вмешательства. Критериями исключения из окончательного анализа являлись следующие условия: возраст менее 14 лет, конверсия (переход на срединную лапаротомию); выполнение дренирования брюшной полости через операционную рану; симультанные вмешательства; вторичный аппендицит; полный отказ от использования шовного материала из индивидуального пакета профилактики ИОХВ». Все полученные в результате исследования сведения были внесены в индивидуальные регистрационные карты (ИРК) с последующим переносом информации в единую электронную базу данных методом двойного ввода. Результаты. В окончательный анализ были включены 322 пациента — 158 (49,0%) женщин и 164 (50,9%) мужчины, средний возраст которых составил 34,8±17,1 года. Средняя длительность госпитализации составила 8,2±2,5 сут. Длительность госпитализации пациентов без и с ИОХВ составила в среднем 7,9±1,8 и 14,2±4,0 сут соответственно (р<0,001). Частота проведения АБП в I и II периодах исследования составила 56,1% (83/148) и 97,7% (170/174) соответственно (р<0,00001). В ИБ 98,9% (90/91) пациентов 1-й группы II периода и 92,8% (77/83) пациентов 2-й группы II периода присутствовал стикер АБП о проведении процедуры. Наиболее часто для профилактики ИОХВ в I периоде использовались цефалоспорины I—IV поколений, общая доля которых составила 85,6% (83/97). Во II периоде исследования в 98,2% (167/170) случаев использовали амоксициллин/клавуланат из индивидуального пакета профилактики ИОХВ. Почти половину всех случаев в I периоде составили случаи в/м введения антибиотика, в/в введение отмечено в 57,3% (55/96). Во II периоде подавляющее большинство случаев было представлено в/в введением препарата — 98,2% (167/170), р<0,0001. В I и II периодах первое введение препарата до разреза (пред­операционная АБП) отмечено у 53,6% (44/82) и 97,1% (165/170) пациентов соответственно (р<0,0001). За оба временных периода исследования ИОХВ в ИБ документирована у 3,7% (12/322) пациентов и недокументирована, по мнению эксперта, еще у 2,5% (8/322) пациентов. Таким образом, частота развития «суммарной ИОХВ» на госпитальном этапе составила 6,2% (20/322). Доля пациентов, с которыми был осуществлен телефонный контакт в оба периода исследования, составила 74,8% (241/322), 56,8% (84/148) и 90,2% (157/174) соответственно. Частота «заявленной ИОХВ», развившейся на госпитальном этапе и после выписки у пациентов в I и II периодах составила 10,1% (15/148) и 12,1% (21/174) соответственно (р>0,05). Абсолютное большинство пациентов 86,1% (31/36) с «заявленной ИОХВ» обращались по этому поводу за медицинской помощью после выписки из стационара. Регистрация «общей ИОХВ» происходило только один раз для одного пациента со следующим приоритетом: ИОХВ диагностирована и документирована на госпитальном этапе, ИОХВ не документирована, заявленная ИОХВ. Таким образом, частота развития общей ИОХВ у всех пациентов в оба временных периода исследования, I и II периодах составила 14,9% (48/322), 15,5% (23/148) и 14,4% (25/174) соответственно. Частота развития общей ИОХВ в 1-й и 2-й группах II периода составила 11,0% (10/91) и 18,1% (15/83) соответственно. Различия не являлись статистически значимыми для всех пар сравнений (р>0,05). При оценке субпопуляции пациентов, с которыми был осуществлен телефонный контакт, частота общей ИОХВ в оба временных периода исследования, I и II периодах 17,4% (42/241), 21,4% (18/84) и 15,3% (24/157) соответственно. Частота развития общей ИОХВ в 1-й и 2-й группах II периода в субпопуляции составила 12,0% (10/83) и 18,9% (14/74) соответственно, р>0,05 для всех пар сравнения. Выводы. ИОХВ после традиционной аппендэктомии остаются актуальной проблемой современной хирургии. Для определения истинной частоты развития ИОХВ необходимо совершенствовать национальную систему регистрации нозокомиальных инфекций. Комплексный подход к профилактике ИОХВ с использованием «индивидуального пакета профилактики ИОХВ» продемонстрировал тенденцию к значительному снижению риска развития таких осложнений в сравнении со стандартизированной АБП и рутинной практикой АБП, что позволяет рекомендовать его для максимального повышения противоинфекционной защиты пациентов. Для достоверного подтверждения этого факта необходимы дальнейшие, более масштабные исследования.

blumox plus capsules

Pyelonephritis is a common infection in childhood and may cause renal scarring. The aim was to determine an effective oral antibiotic treatment of first time pyelonephritis in children.

blumox ca syrup

A successful delivered twin pregnancy.

Target Point Shipping Method Tracking Delivery Time Price
Worldwide shipping

Worldwide shipping

Registered Mail  Not trackable 14-21 business days USD 20.00 per order
EMS  Trackable, where available 5-9 business days USD 30.00 per order

Delivery time is:

Registered Mail - 14-21 business days, prices - USD 20.00, no signature is required on delivery.
EMS - 5-9 business days, prices - USD 30.00, signature is required on delivery.
Your order will be packed safe and secure and dispatched within 24 hours.

front back side

This is exactly how your parcel will look like (pictures of a real shipping item). It has a look of a regular private letter and does not disclose its contents. Size - 9.4x4.3x0.3 inches (24x11x0.7cm).

 Show Hide 
blumox plus capsules 2017-09-26

A questionnaire was posted to BAES members inquiring about experience of major wound infection Amoxicillin Dosage 400mg 5ml following cervicotomy, incidence of minor wound infection, and prophylactic and therapeutic antibiotic usage.

blumox tablet is for 2017-06-03

The west frequent microbe find in the open perineal wounds is Streptococcus group "D" (enterococcus sp.)--53% of the cases and E. coli--26% of the cases. The most frequent microbe find in the open surgical wounds in the Cesarean Section is Enterococcus sp.--42% of the cases and St. aureus--21% of the cases. Ceftin Uti Dosage Considering the effectiveness of Penicillins (Ampicillin, Augmentin, Azlocillin, Karbencillin)--94%-99% against Enterococcus spp. and of Gentamycin against E. coli and St. aureus--90%-95% their application is recommended if is necessary.

tab blumox ca 2015-10-12

We tested the influence of some antibacterial antibiotics on rat sperm motility. Following antibiotics were tested antibacterial influences: amoxicillin + clavulanic acid dose of 30 mg/kg body/day, daily and that 150 mg/kgbody/day, Nisamox Tablets 50mg daily, respectively ceftazidime dose of 50 mg/kgbody/day, daily and that 250 mg/kgbody/day, daily. For each antibiotic and dose was used by a group of rats that received treatment for 12 days for amoxicillin+clavulanic acid and 11 days, respectively 10 days for ceftazidime. A control group of rats was not received and no substance Sperm motility was determined and histopathological examination of tissues was performed harvested.

blumox capsule 2016-03-06

In our study, smoking was the leading risk factor for pneumococcal pneumonia. However, current smokers have an increased risk of bacteremic forms Azomax 200 Mg Syrup and former smokers and patients with COPD developed non-bacteremic forms more frequently. Bacteremic patients need more prolonged intravenous antibiotic treatment than non-bacteremic patients.

blumox ca 625 dosage 2016-09-12

This prospective opened non-comparative clinical trial was conducted in the Department of Surgery, Faculty of Medicine Siriraj Hospital, Bangkok, Thailand between 1 April 2004 and 30 September 2004. Prophylactic amoxycillin/clavulanate (Cavumox) at a dose of 1.2 gram was given intravenously to all patients who underwent emergency or elective intra-abdominal procedures. All patients were scheduled to follow-up visits Flemoxin Solutab Dosage at 7, 14 and 30 days post operatively for monitoring the occurrence of SSI.

blumox ca syrup 2015-11-29

Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is an increasingly important group of community pathogens worldwide. These organisms are frequently resistant to many of the antimicrobial agents usually recommended for the treatment of infections caused by E coli, such as penicillins, cephalosporins, fluoroquinolones, and trimethoprim-sulfamethoxazole. Data concerning risk factors, clinical features, Nolicin Este Antibiotic and therapeutic options for such infections are scarce.

blumox plus tablet uses 2017-01-22

This prospective, randomized, open, international, multicenter study of adults with complicated intra-abdominal infections (cIAI) compared the efficacy and safety of sequential intravenous (i.v.) to oral (p.o.) moxifloxacin 400 mg once daily, with that of i.v. ceftriaxone 2 Medicis Ziana Gel Coupon g once daily, plus metronidazole 500 mg three times daily, followed by p.o. amoxicillin/clavulanate 625 mg three times daily. The primary efficacy variable was clinical cure at test of cure (TOC) (day 28-42 after study entry) in the per protocol (PP) population. Of 595 patients in the study, 511 patients were valid for PP analysis (246 moxifloxacin, 265 ceftriaxone/metronidazole). Sequential moxifloxacin was noninferior to the comparator regimen--clinical cure rates at TOC were 80.9% versus 82.3% (moxifloxacin versus ceftriaxone/metronidazole; 95% CI -8.9, 4.2%). The incidence of adverse events was comparable between the two treatment groups. Therefore, sequential moxifloxacin monotherapy is as effective and safe as combination therapy with i.v. ceftriaxone plus i.v. metronidazole followed by oral amoxicillin/clavulanate for the treatment of cIAI.

blumox dxl dosage 2015-07-17

A 4-year-old castrated male Chihuahua was evaluated because of unilateral vision loss following extraoral administration of a caudal Noroxin Norfloxacin 400 Mg maxillary nerve block during a dental procedure.

tab blumox dxl 2017-12-20

The experimental and clinical values of amoxycillin/clavulanate in severe Staphylococcus aureus infections are reviewed. Experimentally, amoxycillin/clavulanate was highly effective in the treatment of acute endocarditis due to methicillin-sensitive isolates of S. aureus (MSSA) in rats. In addition, high doses of amoxycillin/clavulanate also cured experimental endocarditis due to methicillin-resistant strains of S. aureus (MRSA) in the animal model. In the clinical setting, a review of 86 patients with either community- or hospital-acquired bacteraemia due to MSSA showed that intravenous treatment with amoxycillin/clavulanate was adequate for empirical (and apparently also long-term) therapy of such severe infections. However, the retrospective nature of the analysis did not allow assessment of the relative efficacy of amoxycillin/clavulanate as compared with standard anti-staphylococcal drugs, such as flucloxacillin or vancomycin. Further prospective studies are warranted to address this issue. Thus, amoxycillin/clavulanate appears to be a good candidate for empirical treatment of severe infections that may be caused by MSSA. Usage of amoxycillin/clavulanate against MRSA is, however, still experimental and is not currently advocated for the treatment of MRSA infections in humans.